Recent Biotechnology Acquisitions in Ohio
Acquisition Volume in Biotechnology in Ohio by Year
Last 5 years
-
October 7, 2024
- Buyer
- Calibre Scientific
- Target
- Molecular Research Center, Inc.
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Buyout
Calibre Scientific has acquired Molecular Research Center, Inc. (MRC), an Ohio-based developer and manufacturer of reagents and kits for RNA and DNA isolation and analysis. The acquisition expands Calibre Scientific's life‑science reagent and molecular biology product offering and strengthens its capabilities in nucleic acid isolation technologies.
-
November 13, 2023
- Buyer
- Ajinomoto Co., Inc.
- Target
- Forge Biologics
- Seller
- Forge unitholders
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Buyout
Ajinomoto Co., Inc. will acquire Forge Biologics in an all-cash transaction valued at $620 million, expanding Ajinomoto's gene therapy and plasmid/AAV manufacturing capabilities. Forge, a Columbus, Ohio–based viral vector and plasmid CDMO with a 200,000 sq ft cGMP facility and ~300+ employees, will become a consolidated subsidiary to accelerate global gene and cell therapy manufacturing capacity.
-
June 17, 2023
- Buyer
- Vector Laboratories
- Target
- Quanta BioDesign
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Buyout
Vector Laboratories has acquired Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG) technology, expanding Vector's bioconjugation linkers, dyes and payload delivery capabilities. The Plain City, Ohio-based company's dPEG reagents will broaden Vector's product portfolio and support life science and biopharma customers in therapeutic, diagnostic and research applications.
-
- Buyer
- Eurofins Scientific, Eurofins Clinical Testing US Holdings, Inc.
- Target
- DNA Diagnostics Center (DDC)
- Seller
- GHO Capital Partners LLP (GHO Capital)
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Buyout
Eurofins Scientific, via its subsidiary Eurofins Clinical Testing US Holdings, has entered into an agreement to acquire DNA Diagnostics Center (DDC), a consumer-focused DNA testing laboratory. The deal is expected to expand Eurofins’ reach into consumer genetics and health & wellness markets, with DDC projected to generate over $55M in 2021 revenue and operating from its Fairfield, Ohio facility.
-
January 8, 2020
- Buyer
- Calibre Scientific
- Target
- NeXtal Biotechnologies
- Seller
- Qiagen NV
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Divestiture
Calibre Scientific has acquired the NeXtal Biotechnologies line of structural biology products (including EasyXtal crystallization plates) from Qiagen NV. The purchase expands Calibre's structural biology and protein crystallization product portfolio, supplying academic, biotechnology, and pharmaceutical customers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.